Gene therapy holds promise for treating inherited Lou Gehrig's Disease

CHICAGO --- Using gene therapy in laboratory mice, researchers have halted motor neuron destruction and slowed progression of inherited amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, a lethal, progressive neurological disorder that renders the muscles of the body useless while leaving the mind unaffected.

This finding suggests that a similar gene therapy approach might someday prove effective in treating humans with ALS, according to Northwestern University developmental neurobiologist Martha C. Bohn and colleagues in an article in the July 15 issue of Human Gene Therapy.

Bohn is a professor of pediatrics at Northwestern University Medical School and director of the neurobiology program at Children's Memorial Institute for Education and Research.

Into the hindlimbs of an ALS mouse model, Bohn and co-researchers injected young skeletal muscle cells (myoblasts) infected with a virus that had been made harmless and also engineered to carry the gene for glial cell-derived neurotrophic factor (GDNF). GDNF is a protein that has been found to block nerve cell degeneration in animal models of Parkinson's disease.

The GDNF gene therapy enhanced survival of motor neurons in the laboratory model of inherited ALS and increased the number of motor neurons that maintained 'communication' with cells in treated leg muscles. Additionally, GDNF gene therapy slowed shrinkage of motor neurons and muscle atrophy, improved motor function in affected mice and delayed onset of ALS disease symptoms.

"The most critical issues in designing a gene therapy approach for any human disease are to have a good animal model of the disease and to choose the appropriate target tissue and mode of gene delivery," Bohn said.

The mice used in this study express a mutant gene that is carried by humans with a hereditary form of ALS. These mice were developed by Mark Gurney and Teepu Siddique, professor of neuro

Contact: Elizabeth Crown
Northwestern University

Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:

(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/23/2020)... ... 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical company focused ... an Investigational New Drug application (IND) with the U.S. Food & Drug Administration ... NBTX-001 in patients with panic disorder (PD). , "Adding a PD trial to ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
Breaking Biology Technology:
Cached News: